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Transcriptome analysis of 
inflammation-related gene 
expression in endothelial cells 
activated by complement MASP-1
Endre Schwaner1, Zsuzsanna Németh1, Péter K. Jani1, Erika Kajdácsi1, Márta L. Debreczeni1, 
Zoltán Doleschall2, József Dobó3, Péter Gál3, János Rigó4, Kinga András5, Tamás Hegedűs5 & 
László Cervenak1
Mannan-binding lectin-associated serine protease 1 (MASP-1), the most abundant enzyme of the 
complement lectin pathway, is able to stimulate human umbilical vein endothelial cells (HUVECs) to 
alter the expression of several cytokines and adhesion molecules. This study has assessed to what 
extent MASP-1 is able to modify the transcriptional pattern of inflammation-related (IR) genes in 
HUVECs. We utilized Agilent microarray to analyse the effects of recombinant MASP-1 (rMASP-1) 
in HUVECs, on a set of 884 IR genes. Gene Set Enrichment Analysis showed an overall activation of 
inflammation-related genes in response to rMASP-1. rMASP-1 treatment up- and down-regulated 19 
and 11 IR genes, respectively. Most of them were previously unidentified, such as genes of chemokines 
(CXCL1, CXCL2, CXCL3), inflammatory receptors (TLR2, BDKRB2) and other inflammatory factors 
(F3, LBP). Expression of IR genes changed early, during the first 2 hours of activation. Both p38-
MAPK inhibitor and NFκB inhibitor efficiently suppressed the effect of rMASP-1. We delineated 12 
transcriptional factors as possible regulators of rMASP-1-induced IR genes. Our microarray-based data 
are in line with the hypothesis that complement lectin pathway activation, generating active MASP-1, 
directly regulates inflammatory processes by shifting the phenotype of endothelial cells towards a more 
pro-inflammatory type.
The complement system, a part of the innate immune system has an indispensable role in the elimination of 
extracellular pathogens and necrotic/apoptotic cells. The complement system can be activated through three 
different routes: the classical, the lectin, and the alternative pathways. Lectin pathway is specialized to recognize 
carbohydrate patterns on the pathogen surface, which eventually leads to the activation of the mannan-binding 
lectin-associated serine protease-1 (MASP-1).
Endothelial cells (ECs) form the innermost cellular lining of blood vessels and lymphatics. Endothelium, 
besides having important role in the regulation of several physiological functions, also participates in immuno-
logical/inflammatory processes, including leukocyte homing, antigen presentation, regulation of complement 
system and the clearance of immune complexes. Because of their unique anatomical localization and predispo-
sition to inflammatory factors, the role of ECs in inflammation is crucial. We have previously demonstrated that 
complement MASP-1 induced human umbilical vein endothelial cells (HUVECs) acquire a pro-inflammatory 
phenotype, including activation of Ca2+-mobilization, NFκB, p38-MAPK, JNK, and CREB signaling pathways 
by cleaving protease-activated receptors (PARs)1, 2. Furthermore, MASP-1 stimulated endothelial cells are able to 
recruit neutrophil granulocytes via production of IL-81. We also demonstrated that the expression of E-selectin 
adhesion molecules in HUVECs was upregulated in response to MASP-1, which resulted in increased adherence 
between neutrophils and endothelial cells3.
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Inflammation is an integral, complex part of the immune-mediated response to infection, trauma, and other 
harmful stimuli4, 5. Moreover, it can also involve almost every other cell type or organ, such as liver, brain and 
endothelium. Activation of cells by pro-inflammatory stimuli results in a specific transcriptional output, i.e. the 
activation of a highly coordinated inflammation-related (IR) gene expression program6, 7. However, the triggering 
factors, the localization, as well as the cellular composition of the individual inflammatory reactions are substan-
tially different, thus, several selective expression patterns of IR genes can be identified. These ‘foot-prints’ of tran-
scriptional patterns are known to be distinct in the case of e.g. TNFα, lipopolysaccharide (LPS) or thrombin8–12, 
and required to an adequate response to the various provoking factors. Since the cellular effects of MASP-1 are 
largely unexplored, there is a rather limited knowledge on the portfolio of IR genes regulated by MASP-1.
Therefore, in our current study, we performed genome-wide gene expression profiling using the Human 
Genome Array to analyze the MASP-1-induced IR transcriptional pattern in HUVECs. The microarray technol-
ogy provides the capacity to compare the differential expression of a large number of genes in a single assay13, and 
this is suited to confirm and expand our previous knowledge about the pro-inflammatory effects of MASP-1 on 
HUVECs. The possible pro-inflammatory effects of MASP-1 may contribute to the pathogenesis of inflammatory 
diseases, where endothelium is also involved, such as atherosclerosis, hereditary angioedema and sepsis.
Results
Creating a set of inflammation-related genes. We have previously demonstrated that MASP-1-
induced HUVECs display a pro-inflammatory phenotype1–3. To focus on the expression of inflammation-related 
genes in response to MASP-1, we have created a novel gene set.
According to the hierarchical relationships between various functional categories in Gene Ontology 
Annotation (UniProt-GOA) database, there are 187 biological processes falling into the ‘Inflammatory response’ 
(GO:0006954) category. Based on this ‘Inflammatory response’ category, we generated a list of 642 genes, which 
was expanded with additional 242 IR genes from 4 commercially available Human Inflammation Kits (nCounter 
GX Human Inflammation Kit, nCounter Human Inflammation V2 panel, Human Inflammatory Cytokines & 
Receptors RT² Profiler PCR Array, Inflammatory Response & Autoimmunity PCR Array).
All the analyses with rMASP-1 and other activators were conducted with this set of 884 IR genes 
(Supplementary Table 1).
Identification of rMASP-1-induced inflammation-related genes. Since primary human cell lines 
bear substantial inherent variability, we decided to perform analyses from multiple individual HUVEC lines to 
find responding genes with high fidelity. To examine the rMASP-1 effects on HUVECs, we measured the mRNA 
expression after rMASP-1 treatment in four independent samples. We regarded the median fold change values of 
the four replicates as significantly induced or suppressed by rMASP-1, if they were equal to or higher than 2, or 
equal to or lower than 0.5, respectively. Moreover, we analyzed whether rMASP-1 affected the IR gene set using 
Gene Set Enrichment Analysis (GSEA), which tests whether a given set of genes is represented higher or lower 
(up-regulated or down-regulated genes, respectively) in the rank list of fold changes than the average fold change 
of all genes. We ordered our genes according to the median log fold changes, then divided our IR gene set into 
up- and down-regulated genes, and found that both subsets were significantly skewed toward the top- or bottom 
of the rank list, respectively (Normalized enrichment score (NES) = 1.2, Nominal (NOM) p value = 0.002 for 
up-regulated, NES = −1.13, NOM p = 0.002 for down-regulated).
When analyzed rMASP-1 regulated IR genes, we found that rMASP-1 treatment altered 30 out of 884 (3.39%) 
IR genes in HUVECs, from which 19 were up- and 11 were down-regulated (Table 1). rMASP-1 was found to reg-
ulate a diverse range of IR genes, including adhesion molecules, cytokines and growth factors, and genes involved 
in signal transduction (Table 1).
We have previously described that MASP-1 induced E-Selectin, IL-6 and IL-8 expression in HUVECs, which 
predominantly requires the involvement of p38-MAPK and NFκB signaling pathways2. Thus, to assess the 
involvement of these pathways in the regulation of IR genes, we used commercially available signaling pathway 
inhibitors. HUVECs were pre-incubated with the inhibitors for 30 min and then, treated with 0.6 μM rMASP-1 
for 2 h. The inhibition of gene expression was considered as significant if the effect of rMASP-1 was reduced below 
50% by the inhibitors. p38-MAPK inhibitor suppressed the effect of rMASP-1 more efficiently than NFκB inhib-
itor (83% and 40% of the rMASP-1 altered IR genes, respectively) (Table 1).
Kinetics of inflammation-related gene expression induced by rMASP-1. As we have previously 
described, rMASP-1 rapidly induces IL-6, IL-8 and E-Selectin expression in endothelial cells1, 3. To assess the 
influence of rMASP-1 on the kinetics of the IR gene-expression, HUVECs were treated with 0.6 µM rMASP-1 for 
1, 2 or 6 h and then microarray was performed. The expression of most rMASP-1 regulated IR genes (83%) were 
changed rapidly within 2 h (10% reached maximum fold change at 1 h and 73% at 2 h) (Fig. 1).
Analysis of the transcription factors up-regulating the rMASP-1-induced inflammatory 
genes. Although we showed that p38-MAPK pathway is one of the most important signaling pathways in 
MASP-1-induced adhesion molecule and cytokine production, we also demonstrated the role of other transcrip-
tion factors (TF) and signaling pathways (NFκB, JNK, CREB)1–3. Therefore, we investigated which TFs are asso-
ciated with the 19 up-regulated IR genes affected by rMASP-1. We used HTRI, TRED and Enrichr databases to 
identify the transcriptional regulators of each genes, and Cytoscape to analyze and visualize the collected data 
(Fig. 2). We found 135 TFs involved in the regulation of the up-regulated IR genes, however, most of these TFs 
(86) have binding site at the promoter region of less than the 16% of the rMASP-1-induced IR genes. 37 are 
involved in the regulation of 16–33% of IR genes, whereas 9 and 3 regulate 33–50% and more than 50% of the IR 
genes, respectively. We considered the last two categories of TFs as the potentially most important transcriptional 
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regulators of rMASP-1-induced IR genes. The majority of these TFs are well-known transcriptional regulators of 
the inflammatory processes in endothelial cells (Table 2).
Comparing the effects of rMASP-1 and other pro-inflammatory factors on the IR gene expres-
sion in HUVECs. The signaling pathways, cytokines and adhesion molecules induced by the most investi-
gated factors that provide pro-inflammatory signals to endothelial cells (such as TNFα, thrombin, histamine, or 
LPS) are well characterized1, 3, 14. Therefore, we aimed to assess whether MASP-1 can induce similar pattern of 
gene expression as the above-mentioned factors. The majority of the rMASP-1 altered 30 IR genes (19 up- and 11 
down-regulated) were co-regulated by TNFα, thrombin, histamine, and/or LPS (10, 13, 12, 15 up-regulated IR 
genes and 1, 4, 2, 8 down-regulated IR genes, respectively) (Table 3). Interestingly, we found considerably more 
Functional 
classification
Gene 
symbol
Gene name by HUGO Gene 
Nomenclature Committee 
(HGNC)
Median of 
fold change by 
rMASP-1
NFκB 
inh.
p38 
inh.
Up-regulated
Adhesion
SELE selectin E 3.07 x x
VCAM1 vascular cell adhesion molecule 1 2.08 x x
Cytokines and 
growth factors
CXCL8 C-X-C motif chemokine ligand 8 5.42 x
CXCL1 C-X-C motif chemokine ligand 1 3.47 x x
CXCL3 C-X-C motif chemokine ligand 3 3.32 x x
IL11 interleukin 11 3.17 x x
CXCL2 C-X-C motif chemokine ligand 2 2.66 x x
FGF12 fibroblast growth factor 12 2.32 x x
KITLG KIT ligand 2.24
Signaling
GHSR growth hormone secretagogue receptor 2.78
NFKBID NFKB inhibitor delta 2.48 x
TLR2 toll like receptor 2 2.32 x
BIRC3 baculoviral IAP repeat containing 3 2.29 x x
BDKRB2 bradykinin receptor B2 2.17 x
TGFBR1 transforming growth factor beta receptor 1 2.03 x
Other
KDM6B lysine demethylase 6B 5.52 x
F3 coagulation factor III, tissue factor 4.09 x
HSPB2 heat shock protein family B (small) member 2 2.98 x x
PRG3
proteoglycan 3, pro 
eosinophil major basic 
protein 2
2.31 x
Down-regulated*
Cytokines and 
growth factors IL2 interleukin 2 −2.22 x
Signaling
CREB3L3 cAMP responsive element binding protein 3 like 3 −2.16 x x
ISL1 ISL LIM homeobox 1 −2.22 x
CCR3 C-C motif chemokine receptor 3 −2.30 x
FOXP3 forkhead box P3 −2.48
EDNRB endothelin receptor type B −2.90 x
C5AR2 complement component 5a receptor 2 −2.90 x x
IL17RB interleukin 17 receptor B −2.94 x
Other
LBP lipopolysaccharide binding protein −2.18 x
CHI3L1 chitinase 3 like 1 −2.30
PGLYRP1 peptidoglycan recognition protein 1 −2.49 x
Table 1. List of rMASP-1 regulated inflammation-related genes, their biological function and the effect of 
pathway inhibitors. *Median fold change (FC) of down-regulated genes are presented as −1/FC.
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rMASP-1 up-regulated genes, which were co-induced by all the other activators (7/19), than down-regulated 
genes (1/11).
Verification of Microarray Analysis. To validate the analytical fidelity of microarray results, real-time 
quantitative PCR (qPCR) was performed for 6 target genes in HUVECs treated with rMASP-1 or TNFα (Table 4). 
We chose 3 genes that were up-regulated, 1 that was down-regulated, whereas the expression of 2 genes did not 
change. Furthermore, we previously published qPCR data to evaluate cytokine and adhesion molecule expression 
Figure 1. Kinetics of gene expression induced by rMASP-1. HUVECs were treated with 0.6 µM rMASP-1 for 
1, 2 or 6 h then subjected to microarray analysis. Genes were categorized according to the time of maximal fold 
change.
Figure 2. Transcription factor network of the MASP-1 induced IR genes. The graphical view of the up-
regulated IR genes and the TFs which bind to their promoter regions was created with Cytoscape. Red squares 
represent the IR genes; blue, green, orange, and purple squares represent the TFs, which regulate less than 16%, 
16–33%, 33–50%, and more than 50% of IR genes, respectively.
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in MASP-1 treated HUVECs, and we compared these data with those of microarrays. We found similar expres-
sion pattern in qPCR and microarray results, and Spearman test showed strong correlation (r = 0.834, p < 0.0001) 
between the two methods. The strong correlation between qPCR and microarray data suggests that our microar-
ray data are reliable enough to establish conclusions for sets of genes.
Discussion
In our earlier studies, we have demonstrated that, beside the well-established lectin pathway activating effect, 
complement MASP-1 has an additional pro-inflammatory role mediated by endothelial cells. HUVECs express a 
distinct cytokine- and adhesion molecule pattern in response to MASP-11, 3. Here, we investigated a more general 
inflammatory role of the MASP-1, i.e. the expression of IR genes in endothelial cells by a transcriptomic approach 
using the Agilent Human Genome Array in HUVECs.
To exclude unnecessary or redundant information and to include all the IR genes that we found important in 
our previous studies regarding the pro-inflammatory effects of MASP-1 on HUVECs, we created a novel IR gene 
set assembled from 5 databases. It contains 884 inflammation-related genes. Our IR gene set covers the majority 
of genes from all inflammation-related processes: cell adhesion, cytoskeleton and extracellular matrix reorgani-
zation, arachidonic acid metabolism, production of reactive oxygen species, cytokines and hormones, as well as 
the inflammatory receptors and signaling pathways in the background of these processes.
GSEA analysis is a method more sensitive for the altered expression of a pathway/process specific gene set 
responding jointly to a stimulus than for individual genes. By this method, we found that our IR gene set is sig-
nificantly regulated by rMASP-1.
Furthermore, we identified 19 and 11 IR genes that were up- or down-regulated in HUVECs, respectively. 
rMASP-1 altered IR genes cover the most sub-processes of inflammation, which suggests that MASP-1 has no 
preference for a specific part of the overall inflammatory process. This is not unexpected if we consider that 
e.g. the previously described neutrophil activating effects of MASP-1 via endothelial cells comprise distinct 
processes – chemotaxis and adhesion1, 3 Although thorough description of the 30 rMASP-1 regulated genes is 
beyond the scope of this study, we highlight some of these genes, which may add novel information to the bet-
ter understanding of inflammatory processes. Based on our data, the proportion of chemokines amongst the 
rMASP-1 regulated genes is considerably high. CXCL1/2/3 (GRO1/2/3) are similarly neutrophil chemoattract-
ant15 as CXCL8 (IL-8), which further supports our previous hypothesis that MASP-1 may preferentially recruit 
neutrophils via the activation of endothelial cells. The regulation of LBP and TLR2 suggests synergism between 
complement-based and toll-like receptor-based pattern recognition processes in order to eliminate bacteria with 
Gene 
symbol Name by HGNC Transcriptional control event Activated by
Binding sites in 19 
rMASP-1 induced IR genes
GATA2 GATA binding protein 2
Required for preproendothelin-1 (PPET-1) 
and VCAM-1 gene expresson in endothelial 
cells39, 40
TNFα 14
AR androgen receptor
Inhibition of TNFα-induced VCAM-1 
expression and NF-κB activation41 and 
increasing human monocyte adhesion to 
vascular endothelium42
Testosterone (T) and 
5α-dihydrotestosterone 
(5αDHT)
13
NFKB1 nuclear factor kappa B subunit 1
Regulates expression of E-Selectin, VCAM-1, 
ICAM-1, IL-6, IL-8, MCP-1 in endothelial 
cells1, 3, 43.
TNFα and Thrombin 10
ETS1 ETS proto-oncogene 1
Regulates cyclin-dependent kinase inhibitor 
(p21CIP), PAI-1, VCAM-1, and MCP-1 in 
endothelial cells44.
Ang II, PDGF-BB, and 
TNFα 8
FOXC1 forkhead box C1
Induces CXCR4 expression in endothelial 
cells, controlling CXCL12-stimulated 
migration45.
CXCL12 8
RELA
RELA proto-
oncogene, NF-kB 
subunit
Regulates expression of E-Selectin, VCAM-1, 
ICAM-1, IL-6, IL-8, MCP-1 in endothelial 
cells1, 3, 43.
TNFα and Thrombin 8
FOXL1 forkhead box L1 Regulates the proliferation and differentiation of gastrointestinal epithelium46.
Induced during hepatic 
stellate cell activation 7
GATA1 GATA binding protein 1
Regulates expression of angiogenic factor 
with G-patch and FHA domains 1 (AGGF1) 
in endothelial cells47.
Erythropoietin (Epo) 7
TP53 tumor protein P53
Upregulates developmental endothelial 
locus-1 (Del-1) in endothelial cells, which 
inhibits leukocyte recruitment48.
Variety of cellular stresses 7
FOXP3 forkhead box P3 Specifies the Treg cell lineage49. Activation of CD4 + T cells 6
HIF1A hypoxia inducible factor 1 alpha subunit
Induces endothelins ET-1 and ET-2, and 
VEGF in endothelial cells50. Hypoxia 6
JUN
Jun proto-oncogene, 
AP-1 transcription 
factor subunit
Forms AP-1, the early response transcription 
factor in endothelial cells51. TNFα, Thrombin 6
Table 2. The most important transcriptional factors of rMASP-1 induced IR genes.
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greater efficiency. Finally, we previously described that MASP-1 is able to cleave high molecular weight kin-
inogen resulting bradykinin production16, 17. Now, we found that one of the bradykinin receptors (BDKRB2) 
is also up-regulated in response to MASP-1. Bradykinin-BDKRB2 system is extremely important in hereditary 
angioedema (HAE), a life-threatening rare disease, where the function of C1-inhibitor is diminished18. Low level 
of C1-inhibitor has been considered as a pathogenetic factor because it fails to block kallikrein18, the bradykinin 
forming enzyme. However, C1-inhibitor is also the primary inhibitor of MASP-1, therefore, our results suggest 
an additional pathogenetic pathway in HAE: in the absence of sufficient amount of C1-inhibitor, MASP-1 is 
over-activated upon microbial infection, trauma or sterile inflammation, forms bradykinin by cleaving kininogen 
and up-regulate BDKRB2 on endothelial cells, which together contribute to the increased permeability leading to 
the life-threatening edematous attacks.
We found a rapid pro-inflammatory activation of HUVECs, which appears to be associated with the alteration 
of 83% of rMASP-1 regulated IR genes within 2h. The kinetics of IR gene expression is concordant with our previ-
ous findings, since we described a similarly quick adhesion molecule- and cytokine production at protein level as 
well as an instantly elevated neutrophil chemotaxis and adhesion1, 3. This prompt answer leads to an efficient syn-
chronization of the first line defense mechanisms (i.e. complement and neutrophils) against bacteria and fungi.
Activation of the NFκB and p38-MAPK signaling pathways are critical for the MASP-1-induced inflammatory 
stimulation of HUVECs2. By inhibition of these pathways, we could emphasize that both NFκB and p38-MAPK 
pathways directly contribute to the pro-inflammatory activation of HUVECs.
We identified 135 TFs involved in the induction of the 19 rMASP-1 up-regulated IR genes. However, only 
a small proportion of these TFs takes part in the regulation of a larger set of genes, which may suggest that the 
“promiscuous” TFs are probably more relevant in the MASP-1 signaling events than the TFs regulating only few 
IR genes. This hypothesis is supported by our previous study, we identified NFκB (a master transcription factor 
in inflammation) pathway involvement in MASP-1 signaling processes1, 2, and here we found that most IR genes 
Functional classification rMASP-1 TNFα TR HA LPS
Up-regulated
Adhesion
SELE x x x x
VCAM1 x x x x
Cytokines and growth factors
CXCL8 x x x x
CXCL1 x x x x
CXCL3 x x x x
IL11 x x
CXCL2 x x x x
FGF12
KITLG x x
Signaling
GHSR x
NFKBID x x
TLR2 x
BIRC3 x x x x
BDKRB2 x x
TGFBR1 x x x
Other
KDM6B x x x
F3 x x x x
HSPB2 x
PRG3 x
SUM 10 13 12 15
Down-regulated
Cytokines and growth factors IL2 x
Signaling
CREB3L3 x
ISL1 x
CCR3 x
FOXP3 x
EDNRB x x x x
GPR77 x x x
IL17RB
Other
LBP
CHI3L1 x x
PGLYRP1 x
SUM 1 4 2 8
Table 3. Comparison of the effect of rMASP-1 and other endothelial cell activators (TNFα, thrombin, 
histamine, LPS). TNFα: tumor necrosis factor alpha, TR: thrombin, HA: histamine, LPS: lipopolysaccharide.
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regulated by rMASP-1 have NFκB binding site at their promoter region. Moreover, c-jun, p53 and ETS-1 were 
also found amongst the 12 most “promiscuous” TFs, and all of them are regulated directly by p38-MAPK19, 
20, the most important regulator of MASP-1 signaling pathway1, 3. In contrast to studying TFs involved in the 
up-regulation of genes, assessing down-regulation is far more difficult, since there is no such database available.
Different inflammatory stimuli launch partially distinct gene sets, which results unique biological reac-
tions21–23. Therefore, it is not unexpected that TNFα, histamine, thrombin, and LPS did not regulate the very 
same set of IR genes. On the other hand, there are several IR genes, which are regulated commonly by all acti-
vators mentioned above. rMASP-1 acted similarly to the 4 activators, i.e. their effects overlapped in some extent 
but we also found genes that were regulated by MASP-1 alone. This type of regulation ensures that inflammatory 
responses have some general features (rubor, calor, tumor, dolor according to the Roman encyclopedist Celsus), 
meanwhile each inflammatory process has some distinct features as well (e.g. histamine also induces itching, 
bradykinin triggers more pain receptors, LPS recruits more leukocytes than the other two inflammatory acti-
vators1, 24, 25). Our results suggest that MASP-1 may be an inflammation inducing enzyme, which also has some 
unique features based on the partially overlapping gene expression profile with other activators.
In conclusion, here we presented the very first study on the cellular effects of MASP-1 utilizing bioinfor-
matics approaches. By GSEA method, we showed that the 884 inflammation-related genes were significantly 
over-represented amongst the up- and down-regulated genes, compared to the whole transcriptome. We also found 
several novel rMASP-1 regulated IR genes in HUVECs beyond those that were studied previously. Furthermore, the 
inflammation-related cellular response to rMASP-1 was found to be a rapid process, and we observed similarities 
as well as differences in gene expression compared to other pro-inflammatory activators. These results support our 
previous findings that MASP-1 may be a novel pro-inflammatory mediator, and therefore, it may be an important 
link between complement activation and endothelial cell induced inflammatory processes.
Materials and Methods
Reagents. We used recombinant catalytic fragment of human MASP-1 (CCP1-CCP2-SP, hereinafter: 
rMASP-1). rMASP-1 was expressed in E. coli26, and purified according to Dobó et al.27. The rMASP-1 prepa-
rations were checked and found to be free of bacterial contaminations and could be inhibited by C1-inhibitor 
as described previously1, 3, 28. Briefly, the purity of rMASP-1 preparation exceeded 95%, checked by PAGE, the 
effects of rMASP-1 could be completely abrogated by C1-Inhibitor, whereas neither polymyxin B nor DNase 
blocked its effects. Inversely, the endothelial cell activating capacity (in NFκB translocation assay) of LPS could 
be decreased by polymyxin B, but not by C1-Inhibitor. Synthetic MASP-1 inhibitor SGMI-1 could also block 
the effects of rMASP-1. Lipoteichoic acid and fMLP did not induce NFκB nuclear translocation in HUVEC.  All 
other reagents were purchased from Sigma-Aldrich, unless otherwise stated. Neither rMASP-1 nor the signaling 
pathway inhibitors showed any sign of cytotoxicity within 24 hours in the highest concentrations utilized in the 
array experiments (data not shown).
Preparation and culturing of human umbilical vein endothelial cells (HUVECs). Cells were pre-
pared from fresh umbilical cords obtained during normal deliveries of healthy neonates1, 29. HUVECs were grown 
in gelatin-precoated flasks (Corning® Costar®) in MCDB131 medium (Life Technologies) completed with 5% 
heat-inactivated fetal calf serum (FCS), 2 ng/ml human recombinant epidermal growth factor (R&D Systems), 
1 ng/ml human recombinant basic fibroblast growth factor (Sigma), 0.3% Insulin Transferrin Selenium (Life 
Technologies), 1% Chemically Defined Lipid Concentrate (Life Technologies), 1% Glutamax (Life Technologies), 
1% Penicillin-Streptomycin antibiotics (Sigma), 5 µg/ml Ascorbic acid (Sigma), 250 nM Hydrocortisone (Sigma), 
10 mM Hepes (Sigma), and 7.5 U/ml Heparin. Each experiment was performed on primary HUVEC cultures 
from different individuals before the 4th passage. The study was conducted in conformity with the WMA 
Declaration of Helsinki; its protocol was approved by the Semmelweis University Institutional Review Board (per-
mission number: TUKEB64/2008), and all participants provided their written informed consent before inclusion.
RNA isolation and GeneChip microarray processing. To assess rMASP-1 effect on HUVECs we carried 
out microarrays from four distinct samples. Confluent layers of HUVECs from four individuals were cultured in 6 
well plates and treated for 2 h with 0.6 µM rMASP-1. We also analyzed kinetics, effects of pathway inhibitors and other 
endothelial cell activators on HUVECs. For this purpose, cells were treated for 1, 2 or 6 h with 0.6 µM rMASP-1, or had 
been pre-incubated for 30 min with 2 µM p38-MAPK inhibitor (SB203580) or 5 µM NFκB inhibitor (Bay-11-7082) 
pathway inhibitors and then treated with 2 µM rMASP-1. To compare effect of MASP-1 with other endothelial cell 
activators, cells were treated with thrombin (300 nM), TNFα (10 ng/mL), LPS (100 ng/mL) or histamine (50 µM). Then 
HUVECs were lysed and stored in TRI® reagent. Total RNA purification was performed with NucleospinTM RNA XS 
(Macherey-Nagel), and analyzed by Agilent Bioanalyzer. The RIN of all RNA samples were above 9.
Treatment
Method Validation gene set qPCR data from previous studies
Genes* F3 BMP-2 TGFBR-1 EDNRB ALOX-12 NOX-4 SELE VCAM1 ICAM1 ICAM2 IL6 IL8 IL1A IL1RA MCP1 EDN1 PAI1 PLAT
rMASP-1
qPCR 5.70 1.27 1.85 −1.96 −1.51 −1.34 47.66 9.22 −1.01 −1.16 2.82 16.11 1.19 1.98 2.67 −1.03 1.38 −1.05
MA** 5.72 1.55 1.64 −4.22 −1.69 0.95 3.56 1.50 1.11 −1.00 1.09 5.29 1.18 0.88 1.85 0.82 1.04 0.82
TNFα
qPCR 79.34 3.81 1.06 −3.36 −4.63 2.77
MA** 30.22 4.95 −1.66 −1.67 −1.07 −3.69
Table 4. Comparisons between results from microarray analysis and qPCR. Table 4 contains FC values 
calculated from qPCR and microarray data. *HGNC Gene symbol. **MA: Microarray.
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Microarray analysis. Samples were further processed according to Agilent Two-color Microarray Based 
Gene Expression Analysis Low Input Quick Amp Labeling Kit protocol, and using Agilent Spike-In Kit, following 
the instructions provided by the manufacturer. The experimental protocol is available at: http://www.agilent.com/
cs/library/usermanuals/Public/G4140-90050_GeneExpression_TwoColor_6.9.pdf
Briefly, equal amounts of Cy3-labeled (untreated) and Cy5-labeled (treated) cRNA from samples were simul-
taneously co-hybridized onto the arrayed oligonucleotides on the same G3 Human Gene Expression 8 × 60 K 
v2 Microarray (G4858A) (Agilent Technologies) slide at 65 °C for 17 h using an Agilent Gene Expression 
Hybridization Kit in Agilent’s SureHyb Hybridization Chambers (G2545A). The hybridized microarrays were 
then washed according to manufacturer’s instructions and scanned after washing using an Agilent Microarray 
Scanner (G2505C) at 2 µm resolution and 20-bit color-depth.
Microarray data analysis. The scanned images were processed and analyzed by Agilent GeneSpring 
14.5-GX software. We used fold change (FC) values generated by the software from the array data as the ratio of 
Lowess normalized, background subtracted Cy5/Cy3 signals if they passed the built-in QC analysis of the soft-
ware executed according to the manufacturer’s protocol for two-color experiments. Linearization of the data was 
undertaken by log2 transformation.
All data are available at the Gene Expression Omnibus database at NCBI under the series accession number 
GSE98114.
Validation of Microarray Data. To confirm gene expression changes measured by the microarray, quan-
titative gene expression was analyzed using quantitative real-time PCR (qPCR). Total RNA was isolated, purified 
as described above, and Promega MMLV reverse transcriptase was used for cDNA transcription. qPCR analyses 
were performed by LightCycler® from the same samples used for microarray analysis. All primers have been 
designed by Primer3 (v. 0.4.0) based on NCBI database and purchased from IDT (Coralville, IA) (Table 5). Data 
obtained by both qPCR and microarray were normalized with values of β-actin.
Databases, software and statistics. To create a set of the IR genes, we used the UniProt and Gene 
Ontology Annotation Databases30, 31. For the network building and analysis the Cytoscape 3.3.0 software 
was employed32. To determine the transcription factors of the genes we queried the Human Transcriptional 
Regulation Interactions database (HTRIdb), the Transcriptional Regulatory Element Database (TRED) and the 
Enrichr database33–35.
Gene Set Enrichment Analysis (GSEA) analysis was performed using GSEA version 2.2.3 from the Broad 
Institute (MIT)36, 37. Normalized Enrichment Scores (NES) and Nominal (NOM) p value were calculated.
We utilized the R Foundation for Statistical Computing Platform to perform Spearman correlation test38.
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